 To date, the standard antiviral treatment, including pegylated interferon PEG-IFN plus ribavirin RBV, has relatively low effectiveness in patients infected with genotype 1 and 4, and is associated with important adverse side effects, that lead to treatment interruption in approximately 30 of cases. 